Z17.0 is a supplementary clinical status code used to document the presence of estrogen receptors on malignant tumor cells, primarily in breast cancer diagnostics. This biomarker indicates that the growth of the neoplasm is driven by the hormone estrogen. Identifying ER-positive status is a critical step in oncological management as it serves as a predictive marker for response to endocrine therapies such as Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors (AIs), and Selective Estrogen Receptor Degraders (SERDs). Prognostically, ER-positive tumors often demonstrate a more indolent course and better outcomes in the short term compared to ER-negative variants. This code is never used as a primary diagnosis but must be appended to the relevant malignancy code (e.g., C50 series) to provide a complete clinical profile.
Sequencing Hormone Receptor Status Codes
Example: Diagnosis: Malignant neoplasm of the upper-outer quadrant of the right female breast. Pathology confirms Estrogen Receptor Positive status. Patient started on Anastrozole. Code C50.411 followed by Z17.0 to indicate receptor-positive status affecting treatment choice.
Billing Focus: Code Z17.0 must be used as an additional code, never as a primary diagnosis. It serves to further specify the malignancy coded in the C50 category.
Documenting Receptor Status in Personal History
Example: Follow-up visit for patient with a personal history of Malignant neoplasm of the left breast, status post lumpectomy and radiation. Patient remains on Tamoxifen for her ER positive status. Documentation: Personal history of breast cancer (Z85.3), Estrogen receptor positive status (Z17.0), and long-term use of tamoxifen (Z79.810).
Billing Focus: Ensure laterality of the historical cancer is noted in the history section of the record to support the high-level E/M coding for surveillance.
Linking Pathology Results to the Encounter
Example: Patient seen to review biopsy results. Pathology report dated 10/12/2025 indicates Invasive Ductal Carcinoma, Nottingham Grade 2, Estrogen Receptor Positive (90% staining), Progesterone Receptor Positive. Plan: Refer to Medical Oncology for endocrine therapy initiation.
Billing Focus: Documentation should explicitly link the pathology report date and findings to the encounter to justify the use of Z17.0.
Specificity in Recurrent Malignancy Documentation
Example: Patient presenting with recurrence of breast cancer in the chest wall. Biopsy of the recurrence confirms the tumor remains Estrogen Receptor Positive. Plan: Switch from Letrozole to Fulvestrant. Document: Secondary malignant neoplasm of the skin of the chest (C79.2), personal history of breast cancer (Z85.3), and ER+ status (Z17.0).
Billing Focus: Laterality and site specificity for the secondary neoplasm are required alongside the status code.
Differentiating Hormone Status from Genetic Susceptibility
Example: Documentation: Patient is ER positive and also carries the BRCA1 mutation. Assessment: Malignant neoplasm of the right breast, lower-inner quadrant (C50.311), Estrogen receptor positive status (Z17.0), and Genetic susceptibility to malignant neoplasm of breast (Z15.01).
Billing Focus: Distinctly code both the receptor status and the genetic mutation as they represent different clinical data points.
Standard oncology follow-up for a patient with ER+ breast cancer on endocrine therapy involving medication management and surveillance.
Routine check-in for a stable breast cancer survivor on long-term hormonal therapy with no new concerns.
This is the definitive procedure that yields the data required to assign ICD-10 code Z17.0.
An alternative method to 88360 for identifying ER+ status with potentially higher precision.
While Z17.0 implies hormonal therapy, many patients receive concurrent or sequential non-hormonal injections.
Used for the administration of hormonal agents like Fulvestrant which are given via IM injection for ER+ breast cancer.
The procedure used to obtain the tissue sample that is subsequently tested for ER status.
Part of the ongoing surveillance for patients with a history of ER+ breast cancer.
Initial consultation for a newly diagnosed breast cancer patient where ER status is a primary discussion point for the treatment plan.
Surgical excision provides the whole tumor specimen for comprehensive receptor testing beyond the initial needle biopsy.